Literature DB >> 2388877

Pharmacokinetics of fluconazole in serum and cerebrospinal fluid in a patient with AIDS and cryptococcal meningitis.

T Chin1, I W Fong, A Vandenbroucke.   

Abstract

The detailed pharmacokinetics of fluconazole in serum and cerebrospinal fluid (CSF) were studied in a patient with acquired immunodeficiency syndrome and cryptococcal meningitis, after an intravenous dose of 400 mg. Fluconazole exhibited a serum elimination half-life of 34.2 hours, distribution volume of 0.56 L/kg, and clearance of 0.19 ml/min/kg. Peak CSF concentration occurred at 4 hours after the dose. Overall penetration of fluconazole based on the ratio of areas under the curve of CSF to serum was 70%. The drug exhibited an excellent pharmacokinetic profile for treatment of central nervous system fungal infections.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2388877

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN： 0277-0008            Impact factor:   4.705


  11 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse.

Authors:  R M Bannatyne; P C Cheng; I W Fong
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

3.  Fluconazole pharmacokinetics in burn patients.

Authors:  B A Boucher; S R King; H L Wandschneider; W L Hickerson; S D Hanes; V L Herring; T W Canada; M M Hess
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

4.  Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection.

Authors:  Seunghoon Han; Jimyon Kim; Haejun Yim; Jun Hur; Wonkeun Song; Jongtae Lee; Sangil Jeon; Taegon Hong; Heungjeong Woo; Dong-Seok Yim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

5.  Effects of immunomodulatory and organism-associated molecules on the permeability of an in vitro blood-brain barrier model to amphotericin B and fluconazole.

Authors:  Vasilios Pyrgos; Diane Mickiene; Tin Sein; Margaret Cotton; Andrea Fransesconi; Isaac Mizrahi; Martha Donoghue; Nikkida Bundrant; Su-Young Kim; Matthew Hardwick; Shmuel Shoham; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

Review 7.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

Review 8.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

9.  Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection.

Authors:  S Tett; S Moore; J Ray
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

10.  Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.

Authors:  Ajay Sudan; Joanne Livermore; Susan J Howard; Zaid Al-Nakeeb; Andrew Sharp; Joanne Goodwin; Lea Gregson; Peter A Warn; Tim W Felton; John R Perfect; Thomas S Harrison; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.